Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Core Viewpoint - Trevi Therapeutics, Inc. has successfully closed a public offering of 20,010,000 shares at a price of $5.75 per share, raising approximately $115.1 million in total proceeds before expenses [1]. Group 1: Offering Details - The public offering included 2,610,000 additional shares due to the underwriters' full exercise of their option to purchase more shares [1]. - The offering was managed by Morgan Stanley, Leerink Partners, Stifel, and Cantor as joint book-running managers [2]. - The shares were offered under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3]. Group 2: Company Overview - Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5]. - Haduvio functions as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in controlling chronic cough [5].